scholarly journals A Retrospective Evaluation of Completion Rates, Total Cost, and Adverse Effects for Treatment of Latent Tuberculosis Infection in a Public Health Clinic in Central Massachusetts

2009 ◽  
Vol 49 (3) ◽  
pp. 424-427 ◽  
Author(s):  
Heather Young ◽  
Mireya Wessolossky ◽  
Jeanne Ellis ◽  
Martin Kaminski ◽  
Jennifer S. Daly
Keyword(s):  
Public Health ◽  
Adverse Effects ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Health Clinic ◽  
Completion Rates ◽  
Retrospective Evaluation ◽  
Total Cost ◽  
Public Health Clinic

scholarly journals Initiation and completion rates for latent tuberculosis infection treatment: a systematic review

2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Andreas Sandgren ◽  
Marije Vonk Noordegraaf-Schouten ◽  
Femke van Kessel ◽  
Anke Stuurman ◽  
Anouk Oordt-Speets ◽  
...  
Keyword(s):  
Systematic Review ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Completion Rates ◽  
Infection Treatment

scholarly journals Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study

2018 ◽  
Vol 52 (6) ◽  
pp. 1801470 ◽  
Author(s):  
Lei Gao ◽  
Haoran Zhang ◽  
Henan Xin ◽  
Jianmin Liu ◽  
Shouguo Pan ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
World Health ◽  
Controlled Study ◽  
Short Course ◽  
Significant Difference ◽  
Randomised Controlled ◽  
Active Disease

Latent tuberculosis infection (LTBI) management is now a critical component of the World Health Organization's End TB Strategy.In this randomised controlled trial (Chinese Clinical Trial Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly regimen) were initially designed to be evaluated for rural residents aged 50–69 years with LTBI in China.Due to the increasingly rapid growth and unexpected high frequency of adverse effects, the treatments were terminated early (after 8 weeks for the once-weekly regimen and after 6 weeks for the twice-weekly regimen). In the modified intention-to-treat analysis on the completed doses, the cumulative rate of active disease during 2 years of follow-up was 1.21% (14 out of 1155) in the untreated controls, 0.78% (10 out of 1284) in the group that received the 8-week once-weekly regimen and 0.46% (six out of 1299) in the group that received the 6-week twice-weekly regimen. The risk of active disease was decreased, with an adjusted hazard ratio of 0.63 (95% CI 0.27–1.43) and 0.41 (95% CI 0.15–1.09) for the treatments, respectively. No significant difference was found in the occurrence of hepatotoxicity (1.02% (13 out of 1279) versus 1.17% (15 out of 1279); p=0.704).The short regimens tested must be used with caution among the elderly because of the high rates of adverse effects. Further work is necessary to test the ultrashort regimens in younger people with LTBI.

Sign in / Sign up

Export Citation Format

Share Document